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Abstract  33 
Introduction: Diagnosis of tuberculous meningitis (TBM) is difficult and poses a significant 34 
challenge to physicians worldwide. Recently, nucleic acid amplification (NAA) tests have shown 35 
promise for diagnosis of TBM, although performance has been variable. We undertook a 36 
systematic review and meta-analysis to evaluate the diagnostic accuracy of NAA tests in 37 
cerebrospinal fluid (CSF) samples against culture as the reference standard or a combined 38 
reference standard (CRS) for TBM.  39 
Methods: We searched Embase, PubMed, Web of Science and the Cochrane library for the 40 
relevant records. QUADS-2 tool was used to assess the quality assessment of the studies. 41 
Diagnostic accuracy measures (i.e. sensitivity and specificity) were pooled with a random effects 42 
model. All Statistical analyses were performed with STATA version 14 (Stata Corporation, 43 
College Station, TX, USA), Meta-DiSc version 1.4 (Cochrane Colloquium, Barcelona, Spain) 44 
and RveMan version 5.3 (Copenhagen: The Nordic Cochrane Centre, the Cochrane 45 
Collaboration).  46 
Results: Sixty-three studies were included in final analysis, comprising 1381cases of confirmed 47 
TBM and 5712 non-TBM controls. These 63 studies were divided into two groups comprising 71 48 
datasets (43 in-house tests and 28 commercial tests) that used culture as the reference standard 49 
and 24 datasets (21 in-house tests and 3 commercial tests) that used a CRS. Studies which used a 50 
culture reference standard had better pooled summary estimates compared to studies which used 51 
CRS. The overall pooled estimates of sensitivity, specificity, positive likelihood ratio (PLR) and 52 
negative likelihood ratio (NLR) of NAA tests against culture were 82% (95% CI: 75-87), 99% 53 
(95% CI: 98-99), 58.6 (35.3-97.3) and 0.19 (0.14-0.25), respectively. The pooled sensitivity, 54 
specificity, PLR and NLR of NAA tests against CRS were 68% (95% CI: 41-87), 98% (95% CI: 55 
95-99), 36.5 (15.6-85.3) and 0.32 (0.15-0.70), respectively.  56 
Conclusion: The analysis has demonstrated that the diagnostic accuracy of NAA tests is 57 
currently insufficient to replace culture as a lone diagnostic test. NAA tests may be used in 58 
combination with culture due to the advantage of time to result and in scenarios where culture 59 
tests are not feasible. Further work to improve NAA tests would benefit from standardized 60 
reference standards and the methodology.  61 
Key words: Tuberculous Meningitis; Meta-analysis; diagnostic accuracy.  62 
63 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
3 
 
Introduction 64 
Tuberculosis (TB) remains a global public-health problem with a high mortality rate. According 65 
to the World Health Organization (WHO), in 2017, TB caused an estimated 1.3 million deaths 66 
among human immunodeficiency virus (HIV)-negative people and an additional 300.000 deaths 67 
among HIV-positive people (1). Among all forms of TB, TB meningitis (TBM) is the most 68 
severe form, with substantial mortality (2-4). Approximately 30-40% of patients with TBM die 69 
despite anti-TB treatment (5, 6). Among HIV-infected patients the mortality rate of TBM may 70 
reach more than 60.0% (6). TBM caused by drug-resistant strains of M. tuberculosis has a 71 
mortality rate approaching 100% (7). The presenting clinical features of TBM are similar to 72 
those of other forms of sub-acute meningoencephalitides, making clinical diagnosis difficult and 73 
contributing to TBM’s high mortality risk due to delay in starting treatment (8, 9). Consequently, 74 
delay in diagnosis and start of treatment have a negative impact on patients outcome (8). The 75 
cornerstones of TBM diagnosis remain the same as pulmonary TB: detection of acid-fast bacilli 76 
(AFB) by microscopy of the cerebrospinal fluid (CSF) and bacterial culture (9). Microscopy, 77 
although rapid and inexpensive, has very low sensitivity (approximately 10–20%) (8, 10). 78 
Mycobacterial culture is more sensitive (60–70%), but the results are not available for weeks (5, 79 
11). In many cases, confirmation of TBM cannot be made on the basis of clinical and laboratory 80 
findings and empiric treatment is required (8). In the context of these limitations, several 81 
commercial and in-house nucleic acid amplification (NAA) techniques, have emerged and are in 82 
regular use to overcome the inadequacies of conventional methods of laboratory diagnosis (12). 83 
Beside their speed to diagnosis, ability to simultaneously detect drug resistance and reduce time 84 
to effective treatment, for areas without laboratory infrastructure for culture or high-quality 85 
microscopy, NAA, will have great advantages over the conventional methods. In the past decade, 86 
studies on the diagnostic accuracy of molecular methods for TBM have been published, but 87 
study design and the design of the NAA tests have varied, thus, the exact role of these tests 88 
remains uncertain (12-19). For example, the range of genetic targets used, capacity for on-89 
demand or need for batch testing and time to final report are contributing factors for variation of 90 
NAA performance. Furthermore, newer tests (lipoarabinomannan lateral flow assay, adenosine 91 
deaminase) are currently being evaluated as alternatives to NAA test, hence the need for better 92 
data on the diagnostic accuracy of NAA tests to allow valid comparisons (20, 21). Furthermore, 93 
different case definitions and different reference standard test in studies make comparison of 94 
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research findings difficult. A comprehensive meta-analysis of the diagnostic accuracy of NAA 95 
tests for TBM was published in 2003, which used microbiological diagnosis, microbiological 96 
plus clinical diagnosis and clinical diagnosis as three different reference standards. Newly 97 
developed commercially available tests such as GeneXpert MTB/RIF were not available at that 98 
time (12). In 2014, a WHO systematic review of GeneXpert found a pooled sensitivity of 80.5% 99 
(95% CI 59.0–92.2%) against culture and 62.8% (95% CI 47.7–75.8%) against combined 100 
reference standard (CRS) for extrapulmonary TB (22). These findings led to a WHO 101 
recommendation for use of GeneXpert as a first line test for detection of extrapulmonary TB and 102 
widespread uptake of use worldwide (10, 23). Yet, other NAA tests have not been systemically 103 
investigated and their performance compared to GeneXpert and the reengineered Xpert Ultra is 104 
not clear.  Additionally, subsequent, substantial studies of both GeneXpert, and the Xpert Ultra 105 
have been published since the WHO systematic review.  Therefore, this systematic review was 106 
performed to evaluate the diagnostic accuracy of NAA tests for TBM based on two reference 107 
standard testes; culture confirmed TBM and CRS.  108 
 109 
Methods  110 
Search strategy 111 
We searched all studies published up to November 11, 2018 from the following databases: 112 
Embase, PubMed, Web of Science and the Cochrane library. Search terms used were: 113 
“Mycobacterium tuberculosis”, “tuberculosis”, “tuberculous meningitis”, “meningitis”, 114 
“cerebrospinal fluid”, “CSF”, “molecular diagnostic techniques”, “nucleic acid amplification”, 115 
“diagnosis”, “Polymerase Chain Reaction”, “PCR”, “loop mediated isothermal amplification”, 116 
“LAMP”, “GeneXpert”, “Xpert”, “ligase chain reaction”, “LCx”, “Amplicor”, “ProbeTec”, 117 
“Gen-probe”, “GenoType MTBDR”, “Cobas”, “Roche”, “Abbott” and “Cepheid”. In addition, 118 
we searched references of included articles to find relevant studies. Only studies written in 119 
English were selected. This study was performed according to the Preferred Reporting Items for 120 
Systematic Reviews and Meta-Analyses statement (24).  121 
Study selection 122 
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The studies found through databases that were duplicates were removed using EndNote X7 123 
(Thomson Reuters, New York, NY, USA). Records were initially screened by title and abstract 124 
by two independent reviewers (AP, MJN) to exclude those not related to the current study. The 125 
full-text of potentially eligible records was retrieved and examined. Any discrepancies were 126 
resolved by consensus. 127 
Inclusion criteria  128 
Studies were included if they report a comparison of an NAA test against a reference standard 129 
and provide data necessary for the computation of both sensitivity and specificity. We used the 130 
TBM definition by Thwaites diagnostic index and Marais criteria (8, 25). Briefly, Confirmed 131 
TBM was defined as any patient with positive culture for TBM. Likewise, CRS was definite as 132 
any patients who fulfill clinical criteria plus one or more of the following: acid-fast bacilli seen 133 
in the CSF; Mycobacterium tuberculosis cultured from CSF; or CSF-positive NAA test. Two 134 
reviewers (AP and MJN) independently judged study eligibility. Disagreements were resolved by 135 
consensus. 136 
Exclusion criteria 137 
Studies were excluded if they: did not report confirmed and/or suspected TBM based on 138 
Thwaites and Marais diagnostic criteria, did not report sufficient data for computation of 139 
sensitivity and specificity and did not contain enough samples (≤10 CSF samples).  140 
Data extraction  141 
The following items were extracted from each article: first author, year of publication, study 142 
time, study location, type of NAA test used, reference standard used, number of confirmed TBM 143 
cases, number of suspected TBM cases and number of non-TBM (controls). Two reviewers (AP 144 
and MJN) independently extracted data and differences were resolved by consensus. 145 
Quality assessment  146 
The methodological quality of the studies was  assessed using the QUADAS-2 checklist (26). 147 
Analysis 148 
 149 
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Statistical analyses were performed with STATA (version 14 IC; Stata Corporation, College 150 
Station, TX, USA), Meta-DiSc 1.4 for Windows (Cochrane Colloquium, Barcelona, Spain) and 151 
RveMan Version 5.3 (Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration). 152 
The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence 153 
intervals between NAA tests and reference standard were assessed. A random effects model was 154 
used to pool the estimated effects. Diagnostic accuracy measures [i.e. the summary receiver 155 
operating characteristic (SROC) curve, the summary positive likelihood ratios (PLR), negative 156 
likelihood ratios (NLR) and DOR] were calculated. A value of pooled PLR greater than 10 and 157 
of pooled NLR less than 0.1 were noted as providing convincing diagnostic evidence (27, 28). 158 
The heterogeneity among the studies was assessed using Chi-square test and I-square statistics. 159 
To identify the risk of publication bias, Deek's test was used, based on parametric linear 160 
regression methods (29). Subgroup analysis was conducted using several study characteristics 161 
separately.  162 
Results  163 
Figure 1 summarizes the study selection process. Briefly, we retrieved data from 63 selected 164 
articles comprising 1381 confirmed TBM cases and 5712 non-TBM controls. These 63 studies 165 
were divided into two groups comprising 71 datasets (43 in-house tests and 28 commercial tests) 166 
that used culture as the reference standard and 24 datasets (21 in-house tests and 3 commercial 167 
tests) that used a CRS. Characteristics of the included studies are described in Table 1. The 168 
studies were conducted in 22 different countries: India was the most frequently represented 169 
country (28 out of 63, 44.4%).  170 
Risk of bias assessment 171 
Based on the QUDAS-2 tool, all included records were identified as having a low risk of bias, 172 
thereby increasing the strength of scientific evidence of the current study (Figure 2). The quality 173 
assessment for each included study is provided in Figure S1.  174 
Overall diagnostic accuracy of NAA tests against culture 175 
The overall pooled estimates of sensitivity, specificity, PLR, NLR and DOR of NAA tests 176 
against culture were 82% (95% CI: 75-87), 99% (95% CI: 98-99), 58.6 (35.3-97.3), 0.19 (0.14-177 
0.25) and 314 (169-584), respectively (Table 2, Figure 3). The SROC plot showed an AUC of 178 
98% (96-99) (Figure 4). The Deek’s test result indicated low likelihood for publication bias (P= 179 
0.01). 180 
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 181 
Diagnostic accuracy of in-house tests against culture 182 
The pooled sensitivity and specificity estimates of in-house NAA tests against culture were 87% 183 
(80-92) and 99% (97-99). The PLR, NLR, DOR and AUC estimates were found to be 64.6 (28.4-184 
147.0), 0.13 (0.08-0.20), 372 (165-839) and 98% (97-99), respectively (Table 2, Figure S2, S3).  185 
Diagnostic accuracy of commercial tests against culture 186 
The pooled sensitivity and specificity estimates of commercial tests against culture were 67% 187 
(58-75) and 99% (98-99), respectively. The PLR, NLR, DOR and AUC estimates were found to 188 
be 46.1 (28.3-75.0), 0.33 (0.25-0.43), 139 (71-274) and 98% (96-99), respectively (Table 2, 189 
Figure S4, S5).  190 
Overall diagnostic accuracy of NAA tests against CRS  191 
The overall pooled estimates of sensitivity, specificity, PLR, NLR, DOR and AUC of NAA tests 192 
against CRS were 68% (95% CI: 41-87), 98% (95% CI: 95-99), 36.5 (15.6-85.3), 0.32 (0.15-193 
0.70), 113 (39-331) and 98% (96-99) respectively (Table 2, Figure 5, 6). There was no evidence 194 
of publication bias (Deek’s Test P value was 0.01). 195 
Diagnostic accuracy of in-house tests against CRS 196 
The pooled sensitivity of in-house NAA tests against CRS was 68% (38-88), and the pooled 197 
specificity was 98% (95-1.00) (Table 2, Figure S6, S7). The PLR, NLR, DOR and AUC 198 
estimates were 44.4 (16.0-123.2), 0.32 (0.14-0.75), 138 (41-468) and 98% (96-99), respectively.  199 
Diagnostic accuracy of commercial tests against CRS 200 
The pooled sensitivity of commercial NAA tests against CRS was 53% (33.4-73.4), and the 201 
pooled specificity was 90% (82-95). The PLR, NLR, DOR and AUC estimates were 70 (40.0-202 
124.2), 0.57 (0.24-0.31), 21 (4.2-104.0) and 94% (90-97), respectively (Table 2). 203 
 204 
Between-group comparisons 205 
In group with culture reference standard, NAA tests revealed better pooled summary estimates 206 
[sensitivity=82% (75-87), specificity=99% (95% CI: 98-99), 58.6 (35.3-97.3), NLR = 0.19 (0.14-207 
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0.25), DOR=314 (169-584), AUC=98% (96-99)] as compared to CRS group [sensitivity=68% 208 
(95% CI: 41-87), specificity=98% (95% CI: 95-99), PLR=36.5 (15.6-85.3), NLR=0.32 (0.15-209 
0.70), DOR=113 (39-331), AUC=98% (96-99) (Table 2). 210 
In group with culture reference standard, in-house test has higher sensitivity, PLR and DOR, 211 
comparable specificity and AUC but lower NLR as compared to commercial test. Likewise, in 212 
CRS group, in-house test has higher sensitivity, specificity and DOR, but lower PLR, NLR as 213 
compared to commercial test. 214 
Subgroup analysis 215 
Table 3 shows the subgroup analysis of the studies based on different NAA tests.  216 
 217 
Discussion 218 
Early and accurate diagnosis of TBM is crucial to reduce morbidity and mortality. However, 219 
different case definitions and different reference standards used in various studies makes 220 
comparison of research findings difficult and limits the management of disease. In the present 221 
study, the sensitivity and specificity of different NAA tests was assessed based on two most 222 
reliable reference standard tests (culture confirmed TBM and CRS). Based on the results 223 
obtained from our analysis we identified that the studies with culture reference standard had 224 
better summary estimates as compared to studies used CRS as reference standard. Thus, the 225 
inclusion of confirmed TBM as the main reference standard test could be applied in diagnosing 226 
algorithms which would lead to better management of TBM.  227 
Based on our analysis, the pooled estimates of sensitivity, specificity, PLR, NLR, DOR and 228 
AUC of in-house NAA tests against culture were 87% (80-92), 99% (97-99), 64.6 (28.4-147.0), 229 
0.13 (0.08-0.20), 372 (165-839) and 98% (96-99), respectively. Likewise, the pooled sensitivity, 230 
specificity, PLR, NLR, DOR and AUC for commercial NAA tests against culture were 67% (58-231 
75), 99% (98-99), 46.1 (28.3-75.0), 0.33 (0.25-0.43), 139 (71-274) and 98% (96-99), 232 
respectively. 233 
Although the sensitivity of in-house tests was higher than the commercial NAA tests, the 234 
decontamination process, the DNA extraction protocol, target genes adopted, presence of PCR 235 
inhibitors and the quality of reaction materials are among the factors that may lead to bias in the 236 
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in-house tests. Thus, while these results are encouraging, in-house tests are unlikely to be a 237 
widespread answer for accurate diagnosis of TBM.  238 
The PLR of commercial tests was 46.1, suggesting that patients with TBM have a 46-fold higher 239 
chance of being NAA test-positive compared with patients without TBM. In contrast to findings 240 
from a prior systematic review performed in 2003, we found higher sensitivity of the commercial 241 
tests (12). Furthermore, when comparing our summary estimates of commercial tests to the 242 
previous meta-analysis, the NLR is lower in our study, (0.33 versus 0.44), but not low enough to 243 
rule out TBM with great confidence (12). Thus, our results suggest that a negative commercial 244 
NAA test should not be used alone as a justification to rule out TBM (30). To rule out TBM, the 245 
results of NAA tests should be confirmed by conventional tests such as culture and smear (12). 246 
By contrast, our meta-analysis indicated that a positive commercial NAA result provides a 247 
definite TBM diagnosis (12). Despite suboptimal sensitivity, the rapid turnaround time of 248 
commercial NAA tests compared to culture enhances its role in the early accurate diagnosis of 249 
TBM. In the management of TBM, this rapidity is of great relevance and may improve outcomes 250 
(12).  251 
Recently, GeneXpert MTB/RIF has been a major breakthrough in the diagnosis of TB Meningitis 252 
(10, 13, 31). Likewise, based on the results of a systematic review published in 2014, Xpert was 253 
recommended as the preferred test for diagnosis of TB meningitis by the WHO (22, 32). In our 254 
analysis, the sensitivity and specificity of GeneXpert MTB/RIF assay was 67% and 98%, 255 
respectively, against culture. By comparison, the 2014 meta-analysis by Denkinger and 256 
colleagues reported a pooled sensitivity of 80.5% against culture (22). Cost-effectiveness 257 
analysis of the use of the GeneXpert MTB/RIF assay has been completed and suggests that this 258 
technology is likely to be a highly cost-effective method of TB diagnosis; however, these 259 
analyses were not TBM specific (33-36). 260 
More recently, Bahr et al evaluated the diagnostic performance of the new GeneXpert MTB/RIF 261 
Ultra (Xpert Ultra) for TBM (23). They found Xpert Ultra had 95% sensitivity for TBM 262 
compared to a CRS of any microbiologic test being positive.  When Xpert Ultra was excluded 263 
from the reference standard, sensitivity was 70%.  In both analyses, Xpert Ultra’s sensitivity was 264 
higher than either Xpert or culture, leading the WHO to recommend Xpert Ultra as the initial test 265 
for TBM (23, 32, 37).   266 
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Some limitations of this study should be taken into consideration. First, heterogeneity exists 267 
among the included studies. To explore the heterogeneity of studies, we conducted subgroup, 268 
meta-regression and sensitivity analyses. The subgroup and meta-regression analyses found that 269 
variables such as NAA techniques and standard tests could be probable reasons of heterogeneity. 270 
Second, we could not address the effect of factors such as sample volume, processing steps, 271 
amplification protocols, expertise with NAA tests and laboratory infrastructure on the accuracy of NAA 272 
tests due to a high level of variability in these factors and/or reporting of these factors in the studies. 273 
Finally, as with any systematic review, limitations associated with potential publication bias 274 
should be considered. 275 
Conclusions 276 
The analysis has demonstrated that the diagnostic accuracy of NAA tests is currently insufficient 277 
to replace culture for diagnosis of TBM as a singular test. However, NAA test use in 278 
combination with culture due to more timely results from NAA tests and their ability to detect 279 
dead bacilli should be considered when feasible.  280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 288 
289 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
11 
 
Acknowledgments: 290 
This study is related to the project NO 1396/67225 From Student Research Committee, Shahid 291 
Beheshti University of Medical Sciences, Tehran, Iran. We also appreciate the “Student 292 
Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti University 293 
of Medical Sciences for their financial support of this study.  294 
 295 
Authors' contributions: 296 
Study design: AP, NCB, TDM and MJN.  297 
Literature search, data collection, data analysis and data interpretation: AP, MJN, SMR  298 
Writing: AP, MJN 299 
Manuscript editing: AP, MJN, NCB, TDM. 300 
 301 
Conflict of interest:  302 
We declare that we have no conflicts of interest 303 
 304 
Funding:  305 
“Student Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti 306 
University of Medical Sciences financially support of this study.  307 
 308 
Ethics committee approval:  309 
Not applicable.  310 
 311 
 312 
313 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
12 
 
References: 314 
 315 
1. (WHO) WHO. 2018. Global tuberculosis report 2018. . 316 
2. Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, Thwaites GE, Boulware DR, 317 
Aarnoutse R, Van Crevel R. 2016. GeneXpert MTB/RIF to diagnose tuberculous meningitis: 318 
perhaps the first test but not the last. Clin Infect Dis 62:1133-1135. 319 
3. Török ME, Nghia HDT, Chau TTH, Mai NTH, Thwaites GE, Stepniewska K, Farrar JJ. 2007. 320 
Validation of a diagnostic algorithm for adult tuberculous meningitis. The American journal of 321 
tropical medicine and hygiene 77:555-559. 322 
4. Van Well GT, Paes BF, Terwee CB, Springer P, Roord JJ, Donald PR, van Furth AM, Schoeman JF. 323 
2009. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the 324 
western cape of South Africa. Pediatrics 123:e1-e8. 325 
5. Thwaites G, Chau T, Mai N, Drobniewski F, McAdam K, Farrar J. 2000. Tuberculous meningitis. J 326 
Neurol Neurosurg Psychiatry 68:289-299. 327 
6. van Laarhoven A, Dian S, Ruesen C, Hayati E, Damen MS, Annisa J, Chaidir L, Ruslami R, Achmad 328 
TH, Netea MG. 2017. Clinical parameters, routine inflammatory markers, and LTA4H genotype 329 
as predictors of mortality among 608 patients with tuberculous meningitis in Indonesia. The 330 
Journal of infectious diseases 215:1029-1039. 331 
7. Vinnard C, King L, Munsiff S, Crossa A, Iwata K, Pasipanodya J, Proops D, Ahuja S. 2017. Long-332 
term mortality of patients with tuberculous meningitis in New York City: a cohort study. Clin 333 
Infect Dis 64:401-407. 334 
8. Thwaites G, Chau T, Stepniewska K, Phu N, Chuong L, Sinh D, White N, Parry C, Farrar J. 2002. 335 
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. The Lancet 336 
360:1287-1292. 337 
9. Mai NT, Thwaites GE. 2017. Recent advances in the diagnosis and management of tuberculous 338 
meningitis. Curr Opin Infect Dis 30:123-128. 339 
10. Bahr NC, Tugume L, Rajasingham R, Kiggundu R, Williams DA, Morawski B, Alland D, Meya DB, 340 
Rhein J, Boulware DR. 2015. Improved diagnostic sensitivity for tuberculous meningitis with 341 
Xpert® MTB/RIF of centrifuged CSF. The International Journal of Tuberculosis and Lung Disease 342 
19:1209-1215. 343 
11. Thwaites GE, Caws M, Chau TTH, Dung NT, Campbell JI, Phu NH, Hien TT, White NJ, Farrar JJ. 344 
2004. Comparison of conventional bacteriology with nucleic acid amplification (amplified 345 
mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of 346 
antituberculosis chemotherapy. J Clin Microbiol 42:996-1002. 347 
12. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM. 2003. Diagnostic accuracy of nucleic 348 
acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. The 349 
Lancet infectious diseases 3:633-643. 350 
13. Nhu NTQ, Heemskerk D, Chau TTH, Mai NTH, Nghia HDT, Loc PP, Ha DTM, Merson L, Van Thinh 351 
TT, Day J. 2014. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. 352 
Journal of clinical microbiology 52:226-233. 353 
14. Rafi W, Venkataswamy MM, Ravi V, Chandramuki A. 2007. Rapid diagnosis of tuberculous 354 
meningitis: a comparative evaluation of in-house PCR assays involving three mycobacterial DNA 355 
sequences, IS6110, MPB-64 and 65 kDa antigen. J Neurol Sci 252:163-168. 356 
15. Deshpande PS, Kashyap RS, Ramteke SS, Nagdev KJ, Purohit HJ, Taori GM, Daginawala HF. 2007. 357 
Evaluation of the IS 6110 PCR assay for the rapid diagnosis of tuberculous meningitis. 358 
Cerebrospinal fluid research 4:10. 359 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
13 
 
16. Quan C, Lu C-Z, Qiao J, Xiao B-G, Li X. 2006. Comparative evaluation of early diagnosis of 360 
tuberculous meningitis by different assays. J Clin Microbiol 44:3160-3166. 361 
17. Bonington A, Strang J, Klapper P, Hood S, Parish A, Swift P, Damba J, Stevens H, Sawyer L, 362 
Potgieter G. 2000. TB PCR in the early diagnosis of tuberculous meningitis: evaluation of the 363 
Roche semi-automated COBAS Amplicor MTB test with reference to the manual Amplicor MTB 364 
PCR test. Tuber Lung Dis 80:191-196. 365 
18. Kulkarni S, Jaleel M, Kadival G. 2005. Evaluation of an in-house-developed PCR for the diagnosis 366 
of tuberculous meningitis in Indian children. J Med Microbiol 54:369-373. 367 
19. Nagdev KJ, Kashyap RS, Parida MM, Kapgate RC, Purohit HJ, Taori GM, Daginawala HF. 2011. 368 
Loop-mediated isothermal amplification for rapid and reliable diagnosis of tuberculous 369 
meningitis. J Clin Microbiol 49:1861-1865. 370 
20. Cox JA, Lukande RL, Kalungi S, Van Marck E, Lammens M, Van de Vijver K, Kambugu A, Nelson 371 
AM, Colebunders R, Manabe YC. 2015. Accuracy of lipoarabinomannan and Xpert MTB/RIF 372 
testing in cerebrospinal fluid to diagnose TB meningitis in an autopsy cohort of HIV-infected 373 
adults. J Clin Microbiol:JCM. 00624-15. 374 
21. Sivakumar P, Marples L, Breen R, Ahmed L. 2017. The diagnostic utility of pleural fluid adenosine 375 
deaminase for tuberculosis in a low prevalence area. The International Journal of Tuberculosis 376 
and Lung Disease 21:697-701. 377 
22. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. 2014. Xpert 378 
MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-379 
analysis. Eur Respir J 44:435-446. 380 
23. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, Bridge SC, Bangdiwala 381 
AS, Meya DB, Denkinger CM. 2018. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous 382 
meningitis in HIV-infected adults: a prospective cohort study. The Lancet infectious diseases 383 
18:68-75. 384 
24. Moher D, Liberati A, Tetzlaff J, Altman DG. 2009. Preferred reporting items for systematic 385 
reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264-269. 386 
25. Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, Donald PR, Wilkinson RJ, 387 
Marais BJ. 2010. Tuberculous meningitis: a uniform case definition for use in clinical research. 388 
The Lancet infectious diseases 10:803-812. 389 
26. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, 390 
Bossuyt PM. 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy 391 
studies. Ann Intern Med 155:529-536. 392 
27. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. 2009. Use of PCR for diagnosis of 393 
invasive aspergillosis: systematic review and meta-analysis. The Lancet infectious diseases 9:89-394 
96. 395 
28. Lu Y, Chen Y-Q, Guo Y-L, Qin S-M, Wu C, Wang K. 2011. Diagnosis of invasive fungal disease using 396 
serum (1→ 3)-β-D-glucan: a bivariate meta-analysis. Intern Med 50:2783-2791. 397 
29. van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. 2014. Investigation of publication 398 
bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC medical 399 
research methodology 14:70. 400 
30. Bahr NC, Marais S, Caws M, Van Crevel R, Wilkinson RJ, Tyagi JS, Thwaites GE, Boulware DR, 401 
Consortium TMIR, Aarnoutse R. 2016. GeneXpert MTB/Rif to diagnose tuberculous meningitis: 402 
perhaps the first test but not the last. Clin Infect Dis 62:1133-1135. 403 
31. Patel VB, Theron G, Lenders L, Matinyena B, Connolly C, Singh R, Coovadia Y, Ndung'u T, Dheda 404 
K. 2013. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a 405 
high burden setting: a prospective study. PLoS Med 10:e1001536. 406 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
14 
 
32. Organization WH. 2013. Automated real-time nucleic acid amplification technology for rapid and 407 
simultaneous detection of tuberculosis and rifampicin resistance: Xpert MT. 408 
33. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, 409 
Kapata N. 2013. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future 410 
prospects for a point-of-care test. The Lancet infectious diseases 13:349-361. 411 
34. Vassall A, van Kampen S, Sohn H, Michael JS, John K, den Boon S, Davis JL, Whitelaw A, Nicol MP, 412 
Gler MT. 2011. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden 413 
countries: a cost-effectiveness analysis. PLoS Med 8:e1001120. 414 
35. Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, 415 
Freedberg KA, Walensky RP. 2012. The cost-effectiveness of routine tuberculosis screening with 416 
Xpert MTB/RIF prior to initiation of antiretroviral therapy in South Africa: a model-based 417 
analysis. AIDS (London, England) 26:987. 418 
36. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y, Rosen S. 419 
2012. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7:e36966. 420 
37. Organization WH. 2017. WHO meeting report of a technical expert consultation: non-inferiority 421 
analysis of Xpert MT. 422 
38. Dil-Afroze, Mir AW, Kirmani A, Eachkoti R, Siddiqi MA. 2008. Improved diagnosis of central 423 
nervous system tuberculosis by MPB64-target PCR. Braz J Microbiol 39:209-213. 424 
39. Baveja C, Gumma V, Manisha J, Choudhary M, Talukdar B, Sharma V. 2009. Newer methods over 425 
the conventional diagnostic tests for tuberculous meningitis: do they really help? Trop Doct 426 
39:18-20. 427 
40. Berwal A, Chawla K, Vishwanath S, Shenoy VP. 2017. Role of multiplex polymerase chain 428 
reaction in diagnosing tubercular meningitis. Journal of laboratory physicians 9:145. 429 
41. Bhigjee AI, Padayachee R, Paruk H, Hallwirth-Pillay KD, Marais S, Connoly C. 2007. Diagnosis of 430 
tuberculous meningitis: clinical and laboratory parameters. Int J Infect Dis 11:348-354. 431 
42. Brienze VMS, Tonon ÂP, Pereira FJT, Liso E, Tognola WA, Santos MAAd, Ferreira MU. 2001. Low 432 
sensitivity of polymerase chain reaction for diagnosis of tuberculous meningitis in southeastern 433 
Brazil. Rev Soc Bras Med Trop 34:389-393. 434 
43. Anonymous. 2012. The Scientific Days of the “Prof. Dr. Matei Bals” National Institute of 435 
Infectious Diseases. J Gastrointestin Liver Dis 21:72. 436 
44. Chaidir L, Ganiem AR, vander Zanden A, Muhsinin S, Kusumaningrum T, Kusumadewi I, van der 437 
Ven A, Alisjahbana B, Parwati I, van Crevel R. 2012. Comparison of real time IS6110-PCR, 438 
microscopy, and culture for diagnosis of tuberculous meningitis in a cohort of adult patients in 439 
Indonesia. PLoS One 7:e52001. 440 
45. Desai D, Nataraj G, Kulkarni S, Bichile L, Mehta P, Baveja S, Rajan R, Raut A, Shenoy A. 2006. 441 
Utility of the polymerase chain reaction in the diagnosis of tuberculous meningitis. Res Microbiol 442 
157:967-970. 443 
46. Haldar S, Sharma N, Gupta V, Tyagi JS. 2009. Efficient diagnosis of tuberculous meningitis by 444 
detection of Mycobacterium tuberculosis DNA in cerebrospinal fluid filtrates using PCR. J Med 445 
Microbiol 58:616-624. 446 
47. San Juan R, Sánchez-Suárez C, Rebollo MJ, Folgueira D, Palenque E, Ortuño B, Lumbreras C, 447 
Aguado JM. 2006. Interferon γ quantification in cerebrospinal fluid compared with PCR for the 448 
diagnosis of tuberculous meningitis. J Neurol 253:1323-1330. 449 
48. Lekhak SP, Sharma L, Rajbhandari R, Rajbhandari P, Shrestha R, Pant B. 2016. Evaluation of 450 
multiplex PCR using MPB64 and IS6110 primers for rapid diagnosis of tuberculous meningitis. 451 
Tuberculosis 100:1-4. 452 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
15 
 
49. Michael JS, Lalitha M, Cherian T, Thomas K, Mathai D, Abraham O, Brahmadathan K. 2002. 453 
Evaluation of polymerase chain reaction for rapid diagnosis of tuberculous meningitis. Indian J 454 
Tuberc 49:133-138. 455 
50. Miörner H, Sjöbring U, Nayak P, Chandramuki A. 1995. Diagnosis of tuberculous meningitis: a 456 
comparative analysis of 3 immunoassays, an immune complex assay and the polymerase chain 457 
reaction. Tuber Lung Dis 76:381-386. 458 
51. Modi M, Sharma K, Sharma M, Sharma A, Sharma N, Sharma S, Ray P, Varma S. 2016. 459 
Multitargeted loop-mediated isothermal amplification for rapid diagnosis of tuberculous 460 
meningitis. The International Journal of Tuberculosis and Lung Disease 20:625-630. 461 
52. Nagdev KJ, Kashyap RS, Deshpande PS, Purohit HJ, Taori GM, Daginawala HF. 2010. 462 
Determination of polymerase chain reaction efficiency for diagnosis of tuberculous meningitis in 463 
Chelex-100® extracted DNA samples. The International Journal of Tuberculosis and Lung Disease 464 
14:1032-1038. 465 
53. Nagdev KJ, Kashyap RS, Deshpande PS, Purohit HJ, Taori GM, Daginawala HF. 2010. Comparative 466 
evaluation of a PCR assay with an in-house ELISA method for diagnosis of Tuberculous 467 
meningitis. Med Sci Monit 16:CR289-CR295. 468 
54. Nagdev KJ, Kashyap RS, Parida MM, Kapgate RC, Purohit HJ, Taori GM, Daginawala HF. 2011. 469 
Loop-mediated isothermal amplification for rapid and reliable diagnosis of tuberculous 470 
meningitis. J Clin Microbiol. 471 
55. Nagdev KJ, Bhagchandani SP, Bhullar SS, Kapgate RC, Kashyap RS, Chandak NH, Daginawala HF, 472 
Purohit HJ, Taori GM. 2015. Rapid diagnosis and simultaneous identification of tuberculous and 473 
bacterial meningitis by a newly developed duplex polymerase chain reaction. Indian J Microbiol 474 
55:213-218. 475 
56. Narayanan S, Parandaman V, Narayanan P, Venkatesan P, Girish C, Mahadevan S, Rajajee S. 476 
2001. Evaluation of PCR using TRC4 and IS6110 primers in detection of tuberculous meningitis. J 477 
Clin Microbiol 39:2006-2008. 478 
57. Nguyen LN, Kox LF, Pham LD, Kuijper S, Kolk AH. 1996. The potential contribution of the 479 
polymerase chain reaction to the diagnosis of tuberculous meningitis. Arch Neurol 53:771-776. 480 
58. Palomo FS, Rivero MGC, Quiles MG, Pinto FP, Machado AMdO, Carlos Campos Pignatari A. 2017. 481 
Comparison of DNA extraction protocols and molecular targets to diagnose tuberculous 482 
meningitis. Tuberculosis research and treatment 2017. 483 
59. Portillo-Gomez L, Morris S, Panduro A. 2000. Rapid and efficient detection of extra-pulmonary 484 
Mycobacterium tuberculosis by PCR analysis. The International Journal of Tuberculosis and Lung 485 
Disease 4:361-370. 486 
60. Rafi W, Venkataswamy M, Nagarathna S, Satishchandra P, Chandramuki A. 2007. Role of IS6110 487 
uniplex PCR in the diagnosis of tuberculous meningitis: experience at a tertiary neurocentre. The 488 
International Journal of Tuberculosis and Lung Disease 11:209-214. 489 
61. Rana S, Chacko F, Lal V, Arora S, Parbhakar S, Sharma SK, Singh K. 2010. To compare CSF 490 
adenosine deaminase levels and CSF-PCR for tuberculous meningitis. Clin Neurol Neurosurg 491 
112:424-430. 492 
62. Rios-Sarabia N, Hernández-González O, Gordillo G, Vázquez-Rosales G, Muñoz-Pérez L, Torres J, 493 
Maldonado-Bernal C. 2016. Identification of Mycobacterium tuberculosis in the cerebrospinal 494 
fluid of patients with meningitis using nested PCR. Int J Mol Med 38:1289-1295. 495 
63. Sastry AS, Sandhya Bhat K K. 2013. The diagnostic utility of Bact/ALERT and nested PCR in the 496 
diagnosis of tuberculous meningitis. Journal of clinical and diagnostic research: JCDR 7:74. 497 
64. Shankar P, Manjunath N, Mohan K, Prasad K, Behari M, Ahuja G. 1991. Rapid diagnosis of 498 
tuberculous meningitis by polymerase chain reaction. The lancet 337:5-7. 499 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
16 
 
65. Sharma K, Sharma A, Singh M, Ray P, Dandora R, Sharma SK, Modi M, Prabhakar S, Sharma M. 500 
2010. Evaluation of polymerase chain reaction using protein b primers for rapid diagnosis of 501 
tuberculous meningitis. Neurol India 58:727. 502 
66. Kusum S, Aman S, Pallab R, Kumar SS, Manish M, Sudesh P, Subhash V, Meera S. 2011. Multiplex 503 
PCR for rapid diagnosis of tuberculous meningitis. J Neurol 258:1781-1787. 504 
67. Kusum S, Manish M, Kapil G, Aman S, Pallab R, Kumar S. 2012. Evaluation of PCR using MPB64 505 
primers for rapid diagnosis of tuberculosis meningitis. Open Access Sci Rep 1:1e4. 506 
68. Sharma K, Modi M, Kaur H, Sharma A, Ray P, Varma S. 2015. rpoB gene high-resolution melt 507 
curve analysis: a rapid approach for diagnosis and screening of drug resistance in tuberculous 508 
meningitis. Diagn Microbiol Infect Dis 83:144-149. 509 
69. Sumi M, Mathai A, Reuben S, Sarada C, Radhakrishnan V, Indulakshmi R, Sathish M, Ajaykumar 510 
R, Manju Y. 2002. A comparative evaluation of dot immunobinding assay (Dot-Iba) and 511 
polymerase chain reaction (PCR) for the laboratory diagnosis of tuberculous meningitis. Diagn 512 
Microbiol Infect Dis 42:35-38. 513 
70. Baker CA, Cartwright CP, Williams DN, Nelson SM, Peterson PK. 2002. Early detection of central 514 
nervous system tuberculosis with the Gen-Probe nucleic acid amplification assay: utility in an 515 
inner city hospital. Clin Infect Dis 35:339-342. 516 
71. Causse M, Ruiz P, Gutiérrez-Aroca JB, Casal M. 2011. Comparison of two molecular methods for 517 
rapid diagnosis of extrapulmonary tuberculosis. J Clin Microbiol 49:3065-3067. 518 
72. Chedore P, Jamieson F. 2002. Rapid molecular diagnosis of tuberculous meningitis using the 519 
Gen-probe Amplified Mycobacterium Tuberculosis direct test in a large Canadian public health 520 
laboratory. The International Journal of Tuberculosis and Lung Disease 6:913-919. 521 
73. Chua H, Tay L, Wang S, Chan Y. 2005. Use of ligase chain reaction in early diagnosis of 522 
tuberculous meningitis. Ann Acad Med Singapore 34:149-53. 523 
74. Johansen IS, Lundgren B, Tabak F, Petrini B, Hosoglu S, Saltoglu N, Thomsen VØ. 2004. Improved 524 
sensitivity of nucleic acid amplification for rapid diagnosis of tuberculous meningitis. J Clin 525 
Microbiol 42:3036-3040. 526 
75. Jönsson B, Ridell M. 2003. The Cobas Amplicor MTB test for detection of Mycobacterium 527 
tuberculosis complex from respiratory and non-respiratory clinical specimens. Scand J Infect Dis 528 
35:372-377. 529 
76. Khan AS, Ali S, Khan MT, Ahmed S, Khattak Y, Irfan M, Sajjad W. 2018. Comparison of GeneXpert 530 
MTB/RIF assay and LED-FM microscopy for the diagnosis of extra pulmonary tuberculosis in 531 
Khyber Pakhtunkhwa, Pakistan. Braz J Microbiol. 532 
77. Notkins AL, Lernmark Å. 2001. Autoimmune type 1 diabetes: resolved and unresolved issues. 533 
The Journal of clinical investigation 108:1247-1252. 534 
78. Malbruny B, Le Marrec G, Courageux K, Leclercq R, Cattoir V. 2011. Rapid and efficient detection 535 
of Mycobacterium tuberculosis in respiratory and non-respiratory samples. The International 536 
Journal of Tuberculosis and Lung Disease 15:553-555. 537 
79. Moure R, Martín R, Alcaide F. 2012. Effectiveness of an integrated real-time PCR method for 538 
detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary 539 
samples in an area of low tuberculosis prevalence. J Clin Microbiol 50:513-515. 540 
80. Patel VB, Connolly C, Singh R, Lenders L, Matinyenya B, Theron G, Ndung'u T, Dheda K. 2014. 541 
Comparison of Amplicor and GeneXpert MTB/RIF tests for diagnosis of tuberculous meningitis. J 542 
Clin Microbiol 52:3777-3780. 543 
81. Pink F, Brown T, Kranzer K, Drobniewski F. 2016. Evaluation of Xpert MTB/RIF for Detection of 544 
Mycobacterium tuberculosis in Cerebrospinal Fluid. J Clin Microbiol 54:809-811. 545 
82. Rakotoarivelo R, Ambrosioni J, Rasolofo V, Raberahona M, Rakotosamimanana N, Andrianasolo 546 
R, Ramanampamonjy R, Tiaray M, Razafimahefa J, Rakotoson J. 2018. Evaluation of the Xpert 547 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
17 
 
MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis 548 
in Madagascar. Int J Infect Dis 69:20-25. 549 
83. Rufai SB, Singh A, Singh J, Kumar P, Sankar MM, Singh S, Team TR. 2017. Diagnostic usefulness of 550 
Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. J Infect. 551 
84. Solomons R, Visser D, Friedrich S, Diacon A, Hoek K, Marais B, Schoeman J, van Furth A. 2015. 552 
Improved diagnosis of childhood tuberculous meningitis using more than one nucleic acid 553 
amplification test. The International Journal of Tuberculosis and Lung Disease 19:74-80. 554 
85. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal M, Pascarella M, Borroni E, Mondo A, Piana F, 555 
Scarparo C. 2012. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary 556 
tuberculosis. Eur Respir J:erj01763-2011. 557 
86. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. 2011. Xpert MTB/RIF, a new 558 
pillar in the diagnosis of extrapulmonary tuberculosis? J Clin Microbiol:JCM. 02319-10. 559 
87. Wang T, Feng G-D, Pang Y, Yang Y-N, Dai W, Zhang L, Zhou L-F, Yang J-L, Zhan L-P, Marais BJ. 560 
2016. Sub-optimal Specificity of Modified Ziehl-Neelsen Staining for Quick Identification of 561 
Tuberculous Meningitis. Front Microbiol 7:2096. 562 
88. Zmak L, Jankovic M, Jankovic VK. 2013. Evaluation of Xpert MTB/RIF assay for rapid molecular 563 
diagnosis of tuberculosis in a two-year period in Croatia. International journal of 564 
mycobacteriology 2:179-182. 565 
 566 
 567 
568 
 o
n
 M
ay 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
18 
 
Figures: 569 
 570 
 571 
Figure 1. Flow diagram of literature search and study selection.    572 
 573 
 574 
Figure 2.  QUADAS-2 assessments of included studies.   575 
Patient Selection: Describe methods of patient selection; Index Text: Describe the index test and how it 576 
was conducted and interpreted; Reference Standard: Describe the reference standard (gold standard test) 577 
and how it was conducted and interpreted; Flow and Timing: Describe any patients who did not receive 578 
the index tests or reference standard or who were excluded from the 2 × 2 table, and describe the interval 579 
and any interventions between index tests and the reference standard (26). 580 
  581 
 582 
 583 
Figure 3. Paired forest plots of pooled sensitivity and specificity of NAA tests against culture.  584 
 585 
 586 
Figure 4. Summary receiver operating characteristic (SROC) plot for NAA tests against culture.  587 
The SROC plot shows summary of test performance, visual assessment of threshold effect, and 588 
heterogeneity of data in ROC space between sensitivity and specificity; each circle in the SROC 589 
plot represents a single study, summary operating sensitivity specificity, and SROC curve with 590 
both confidence and prediction regions. The dashed line that is around the pooled point estimate 591 
shows 95% confidence region. The area under the curve (AUC), acts as an overall measure for 592 
test performance. Particularly, when AUC would be between, 0.8 to 1, the accuracy is relatively 593 
high. As a matter of fact, AUC was 0.52 in this report which represented a relatively moderate 594 
level of accuracy. If SROC curve was in the upper left corner it would showed the best 595 
combination of sensitivity and specificity for the diagnostic test. 596 
 597 
 598 
 599 
Figure 5. Paired forest plots of pooled sensitivity and specificity of NAA tests against CRS.  600 
 601 
 602 
 603 
 604 
Figure 6. Summary receiver operating characteristic (SROC) plot for NAA tests against CRS.  605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
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 614 
Table 1. Characterization of included studies. 615 
First author Country Published 
year 
NAA test Diagnostic 
method 
Gene target Reference 
standard 
No. of 
confirmed 
TBM 
No. of 
Non-TBM 
(Control) 
Study 
design 
 
Consecutive  
sampling 
Data 
collection 
Blinded 
Afroze*(38) India 2008 In-house Conventional PCR MPB64 CRS 27 10 CC NM R Yes 
Baveja (39) India 2009 In-house Conventional PCR IS6110 CRS 22 78 CS Yes P NM 
Berwal (40) India 2017 In-house Conventional PCR IS6110 CRS 26 48 CS NM P NM 
Bhigjee1 (41) 
South 
Africa 
2007 In-house Conventional PCR IS6110 Culture 20 24 CS NM P Yes 
Bhigjee2 (41) 
South 
Africa 
2007 In-house Conventional PCR MPB64 Culture 20 24 CS NM P Yes 
Bhigjee3 (41) 
South 
Africa 
2007 In-house Conventional PCR Pt8/Pt9 Culture 20 24 CS NM P Yes 
Bhigjee4 (41) 
South 
Africa 
2007 In-house Real-time PCR IS6110 Culture 20 24 CS NM P Yes 
Brienze1 (42) Brazil 2001 In-house Nested PCR MPB64 CRS 15 50 CS NM P NM 
Caws (43) 
United 
Kingdom 
2000 In-house Conventional PCR IS6110 Culture 4 105 CS Yes P NM 
Chaidir (44) Indonesia 2012 In-house Real-time PCR IS6110 Culture 102 105 CS Yes P Yes 
Desai1 (45) India 2006 In-house Conventional PCR 
(QIAmp protocol) 
IS6110 CRS 8 27 CS Yes P NM 
Desai2 (45) India 2006 In-house Conventional PCR 
(CTAB protocol) 
IS6110 CRS 8 27 CS Yes P NM 
Deshpande (15) India 2007 In-house Conventional PCR IS6110 CRS 35 29 CC NM P NM 
Haldar1 (46) India 2009 In-house Conventional PCR 
(filtrate protocol) 
IS6110 Culture 10 86 CS NM NM Yes 
Haldar2 (46) India 2009 In-house Conventional PCR 
(sediment protocol) 
IS6110 Culture 10 86 CS NM NM Yes 
Haldar3 (46) India 2009 In-house Conventional PCR 
(filtrate protocol) 
devR Culture 10 86 CS NM NM Yes 
Haldar4 (46) India 2009 In-house Conventional PCR 
(sediment protocol) 
devR Culture 10 86 CS NM NM Yes 
Haldar5 (46) India 2009 In-house Real-time PCR 
(filtrate protocol) 
devR Culture 10 86 CS NM NM Yes 
Haldar6 (46) India 2009 In-house Real-time PCR 
(sediment protocol) 
devR Culture 10 86 CS NM NM Yes 
Haldar7 (15) India 2012 In-house Conventional PCR devR Culture 29 338 CS NM P Yes 
Juan (47) Spain 2006 In-house Conventional PCR IS6110 CRS 12 59 CS Yes P NM 
Kulkarni1*(18) India 2005 In-house Conventional PCR 
(ETBR protpcol) 
Protein b CRS 30 30 CS NM NM Yes 
Kulkarni2 (18) India 2005 In-house Conventional PCR 
(southern protocol) 
Protein b CRS 30 30 CS NM NM Yes 
Lekhak1*(48) Nepal 2016 In-house Conventional PCR IS6110 CRS 37 75 CS NM NM NM 
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Lekhak2 (48) Nepal 2016 In-house Conventional PCR MPB64 CRS 37 75 CS NM NM NM 
Michael (49) India 2002 In-house Conventional PCR IS6110 Culture 17 68 CS NM R Yes 
Miorner (50) India 1995 In-house Conventional PCR IS6110 Culture 6 34 CC NM NM NM 
Modi1 (51) India 2016 In-house Conventional PCR IS6110 Culture 50 100 CS NM NM NM 
Modi2 (51) India 2016 In-house LAMP PCR IS6110 Culture 50 100 CS NM NM NM 
Modi3 (51) India 2016 In-house LAMP PCR MPB64 Culture 50 100 CS NM NM NM 
Nagdev1 (52) India 2010 In-house Nested PCR IS6110 Culture 1 13 CC NM NM NM 
Nagdev2 (53) India 2010' In-house Conventional PCR IS6110 Culture 13 139 CC NM P NM 
Nagdev3*(54) India 2011 In-house Nested PCR IS6110 CRS 17 10 CC NM R NM 
Nagdev4 (54) India 2011 In-house LAMP PCR IS6110 CRS 17 10 CC NM R NM 
Nagdev5 (55) India 2015 In-house Multiplex PCR 16s rDNA Culture 8 85 CS NM P NM 
Nagdev6 (55) India 2015 In-house Multiplex PCR IS6110 Culture 8 85 CS NM P NM 
Narayanan1 (56) India 2001 In-house Conventional PCR IS6110 Culture 20 8 CS NM NM NM 
Narayanan2 (56) India 2001 In-house Conventional PCR TRC4 Culture 20 8 CS NM NM NM 
Nguyen (57) Vietnam 1996 In-house Conventional PCR IS6110 Culture 17 32 CS Yes R Yes 
Palomo1*(58) Brazil 2017 In-house Conventional PCR IS6110 CRS 35 65 CS NM NM NM 
Palomo2 (58) Brazil 2017 In-house Conventional PCR MBP64 CRS 35 65 CS NM NM NM 
Palomo3 (58) Brazil 2017 In-house Conventional PCR hsp65 CRS 35 65 CS NM NM NM 
Portillo (59) Mexico 2000 In-house Conventional PCR IS6110 Culture 13 113 CS NM NM NM 
Quan (16) China 2006 In-house Conventional PCR IS6110 Culture 3 49 CC NM NM NM 
Rafi1 (14) India 2007 In-house Conventional PCR IS6110 Culture 45 75 CS NM R Yes 
Rafi2 (14) India 2007 In-house Nested PCR MPB64 Culture 45 75 CS NM R Yes 
Rafi3 (14) India 2007 In-house Nested PCR 65 Kda Culture 45 75 CS NM R Yes 
Rafi4 (60) India 2007 In-house Conventional PCR IS6110 Culture 136 268 CS NM P Yes 
Rana (61) India 2010 In-house Conventional PCR IS6110 Culture 5 37 CS NM P NM 
Rios-Sarabia1*(62) Mexico 2016 In-house Multiplex PCR Protein b CRS 50 50 CC Yes P Yes 
Rios-Sarabia2 (62) Mexico 2016 In-house Multiplex PCR IS6110 CRS 50 50 CC Yes P Yes 
Rios-Sarabia3 (62) Mexico 2016 In-house Multiplex PCR MPB40 CRS 50 50 CC Yes P Yes 
Rios-Sarabia4 (62) Mexico 2016 In-house Nested PCR MPB40 CRS 50 50 CC Yes P Yes 
Sastry (63) India 2013 In-house Nested PCR IS6110 Culture 2 33 CC Yes P NM 
Shankar (64) India 1991 In-house Conventional PCR MPB64 Culture 4 51 CS NM NM NM 
Sharma1 (65) India 2010 In-house Conventional PCR Protein b Culture 10 40 CS NM NM NM 
Sharma2 (66) India 2011 In-house Multiplex PCR IS6110 Culture 18 100 CS Yes NM Yes 
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Sharma3 (66) India 2011 In-house Multiplex PCR MPB64 Culture 18 100 CS Yes NM Yes 
Sharma4 (66) India 2011 In-house Multiplex PCR Protein b Culture 18 100 CS Yes NM Yes 
Sharma5 (67) India 2012 In-house Conventional PCR MPB64 Culture 9 40 CS NM P NM 
Sharma6 (68) India 2015 In-house Real-time PCR IS6110 Culture 12 120 CS NM NM NM 
Sharma7 (68) India 2015 In-house Real-time PCR MPB64 Culture 12 120 CS NM NM NM 
Sharma8 (68) India 2015 In-house Real-time PCR rpoB Culture 12 120 CS NM NM NM 
Sumi (69) India 2002 In-house Conventional PCR IS6110 Culture 8 45 CC NM NM Yes 
Bahr1 (10) Uganda 2015 Commercial GeneXpert rpoB Culture 18 89 CS NM NM NM 
Bahr2 (23) Uganda 2018 Commercial GeneXpert Ultra 
rpoB, 
IS6110, 
IS1081 
Culture 22 107 CS NM P NM 
Baker (70) 
United 
States 
2002 Commercial Gen-probe MTD 16s RNA Culture 5 24 CS NM NM Yes 
Bonington (17) 
South 
Africa 
2000 Commercial 
Cobas Amplicor 
MTB 
16s RNA Culture 8 29 CS NM P NM 
Brienze2 (42) Brazil 2001 Commercial 
Cobas Amplicor 
MTB 
16s RNA CRS 11 17 CS NM P NM 
Causse1 (71) Spain 2011 Commercial GeneXpert rpoB Culture 6 299 CS Yes NM NM 
Causse2 (71) Spain 2011 Commercial Cobas Amplicor 
MTB 
16s RNA Culture 6 299 CS Yes NM NM 
Chedore (72) Canada 2002 Commercial Gen-probe MTD 16s RNA Culture 16 295 CS NM NM NM 
Chua (73) Singapore 2005 Commercial 
Abbott LCx ligase 
chain reaction 
Protein b Culture 6 36 CC NM P NM 
Cox (20) Uganda 2015 Commercial GeneXpert rpoB CRS 8 69 CS NM NM NM 
Johansen (74) Denmark 2004 Commercial ProbeTec IS6110 Culture 13 88 CS NM NM NM 
Jönsson (75) Sweden 2003 Commercial 
Cobas Amplicor 
MTB 
16s RNA Culture 9 145 CS Yes R NM 
Khan (76) Pakistan 2018 Commercial GeneXpert rpoB Culture 12 47 CS NM NM NM 
Lang (1) 
Dominican 
Republic 
1998 Commercial Gen-probe MTD 16s RNA Culture 5 60 CS Yes P NM 
Li (77) China 2017 Commercial GeneXpert rpoB Culture 4 70 CS Yes NM NM 
Malbruny (78) France 2011 Commercial GeneXpert rpoB Culture 1 14 CS Yes P NM 
Moure (79) Spain 2011 Commercial GeneXpert rpoB Culture 2 12 CS NM NM NM 
Nhu (13) Vietnam 2013 Commercial GeneXpert rpoB Culture 151 197 CS Yes P Yes 
Patel1 (80) 
South 
Africa 
2014 Commercial GeneXpert rpoB Culture 31 53 CS Yes P Yes 
Patel2 (80) 
South 
Africa 
2014 Commercial 
Cobas Amplicor 
MTB 
16s RNA Culture 31 53 CS Yes P Yes 
Pink (81) 
United 
Kingdom 
2016 Commercial GeneXpert rpoB Culture 37 703 CS NM NM NM 
Rakotoarivelo (82) Madagascar 2018 Commercial GeneXpert rpoB Culture 13 31 CS NM NM NM 
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Rufai (83) India 2017 Commercial GeneXpert rpoB Culture 49 212 CS NM NM NM 
Solomons1 (84) 
South 
Africa 
2015 Commercial GenoType 
MTBDRplus 
INH, RIF Culture 13 46 CS Yes P NM 
Solomons2 (84) 
South 
Africa 
2015 Commercial GeneXpert rpoB Culture 13 46 CS Yes P NM 
Thwaites (11) Vietnam 2004 Commercial Gen-probe MTD 16s RNA Culture 42 79 CS Yes P Yes 
Tortoli (85) Italy 2012 Commercial GeneXpert rpoB Culture 13 120 CS NM R Yes 
Vadwai1 (86) India 2011 Commercial GeneXpert rpoB CRS 7 15 CS NM NM Yes 
Vadwai2 (86) India 2011 Commercial GeneXpert rpoB Culture 3 19 CS NM NM Yes 
Wang (87) China 2016 Commercial GeneXpert rpoB Culture 13 188 CS NM P Yes 
Zmak (88) Croatia 2013 Commercial GeneXpert rpoB Culture 1 45 CS NM NM NM 
*These studies did not used culture to define confirm TBM.  616 
CRS: combined reference standard, P: prospective, R: retrospective, CS: cross-sectional, CC: case-control, NM: Not mentioned 617 
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 639 
 640 
Table 2. Summary measures of test accuracy for all studies, commercial, and in-house tests. 641 
Test property Sensitivity 
(95% CI, I
2
) 
Specificity 
(95% CI, I
2
) 
PLR (95% CI) NLR (95% CI) DOR (95% CI) AUC (95% CI) 
All studies  
(63 studies) 
Culture (71 datasets 
with 1492 TBM cases) 
82%  
(75-87, 82.4%) 
99%  
(98-99, 85.0%) 
58.6 (35.3-97.3) 0.19 (0.14-0.25) 314 (169-584) 98% (96-99) 
CRS (24 datasets with 
652 TBM cases) 
68%  
(41-87, 83.6%) 
98%  
(95-99, 76.2%) 
36.5 (15.6-85.3) 0.32 (0.15-0.70) 113 (39-331) 98% (96-99) 
Culture 
(71 datasets) 
In-house tests (43 
datasets with 950 TBM 
cases) 
87%  
(80-92, 82.0%) 
99%  
(97-99, 88.5%) 
 
64.6 (28.4-147.0) 0.13 (0.08-0.20) 372 (165-839) 98% (97-99) 
Commercial tests (28 
datasets with 543 TBM 
cases) 
67%  
(58-75, 64.8%) 
99%  
(98-99, 48.3%) 
46.1 (28.3-75.0) 0.33 (0.25-0.43) 139 (71-274) 98% (96-99) 
CRS 
(24 datasets) 
In-house tests (21 
datasets with 626 TBM 
cases) 
68%  
(38-88, 83.5%) 
98%  
(95-100, 78.0%) 
44.4 (16.0-123.2) 0.32 (0.14-0.75) 138 (41-468) 98% (96-99) 
Commercial tests (3 
datasets with 26 TBM 
cases) 
53%  
(33-73, 84.7%) 
90%  
(82-95, 52.2%) 
70.0 (40.0-124.2) 0.57 (0.24-0.31) 21 (4.2-104) 94% (90-97) 
CRS: combined reference standard, PLR: positive likelihood ratio, NLR: negative likelihood ratio, DOR: diagnostic odds ratio, AUC: area under the curve. 642 
 643 
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 650 
Table 3. Subgroup analysis of studies based on different NAA tests.  651 
Reference 
standard 
Subgroup Subgroup by method No. of  
datasets 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PLR (95% CI) NLR (95% CI) DOR (95% CI) AUC (95% CI) 
Culture 
 
In-house 
 
Conventional PCR 
(IS6110 gene) 18 
87% (77-93) 
98% (94-99) 39.5 (15.7-77.1) 0.13 (0.07-0.25) 307 (106- 888) 98 (96-99) 
Conventional PCR 
(MPB64 gene) 4 
92% (81-  97) 
98% (78-99) 52.0 (3.4-778.4) 0.08 (0.03-0.20) 275 (42-1814) 93 (91-95) 
Nested PCR 
4 
82% (46- 96) 
92% (88-95) 10.7 (5.9-19.4) 0.19 (0.05- 0.79) 55 (9-339) 93 (91-95) 
Real-time PCR 
7 
84% (71-92) 
100% (45-100) 44.0 (5.7- 335.4) 0.16 (0.08,0.65) 255 (40-607) 93 (91-95) 
LAMP PCR 
2 
93% (88 -97) 
100% (98 -100) 68.8 (0.68-925.8) 0.07 (0.03-0.13) - - 
Commercial 
 
Cobas Amplicor 
MTB 4 48% (35- 61) 
98% (97-99) 
 25.3 (12.9-49.7) 
0.53 (0.41-0.68) 48 (21-109) 
94 (91-95) 
GeneXpert 
16 61% (52-70) 99% (97-99) 42.0 (20.6-85.2) 0.39 (0.31- 0.50) 107 (64-251) 92 (89-94) 
Gen-probe MTD 
4 86% (52-97) 99% (95-100) 92.4 (14.8-577.6) 0.15 (0.03- 0.63) 634 (31-1299) 99 (98-100) 
CRS 
 
In-house 
 
Conventional PCR 
(IS6110 gene) 9 87% (46- 98) 98% (88-100) 39.2 (7.8-197.8) 0.13 (0.02- 0.78) 119 (42-332) 99 (97-99) 
Conventional PCR 
(MPB64 gene) 4 27% (02-85) 99% (91-100) 35.9 (1.7-751.1) 0.74 (0.36-1.52) 45 (8-249) 99 (97-99) 
Nested PCR 
3 80% (70 - 88) 95% (0.89-98) 11.9 (5.3-6.7) 0.23 (0.05-1.02) 86 (7-1049) 97 (93-99) 
Commercial 
 
GeneXpert 
2 66% (38- 88) 
89% (80-95) 
7.0 (3.8-12.8) 
0.23 (0.00- 19.53) - - 
CRS: combined reference standard, PLR: positive likelihood ratio, NLR: negative likelihood ratio, DOR: diagnostic odds ratio, AUC: area under the curve. 652 
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